Omalizumab

證據等級: L5

預測適應症: 10 個

Omalizumab: From Allergic Asthma to Bronchitis

One-Sentence Summary

Omalizumab is a humanized anti-IgE monoclonal antibody with internationally established efficacy in severe allergic asthma; it is not currently marketed in Norway. The TxGNN model predicts it may be effective for Bronchitis, with 2 clinical trials and 8 publications currently identified, though most of this evidence comes from asthma populations rather than a confirmed bronchitis diagnosis.

Quick Overview

Item	Content
Original Indication	Not licensed in Norway; internationally recognized for severe allergic asthma (per literature evidence in this pack)
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.9992%
Evidence Level	L3
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information drawn from the attached literature, omalizumab is a humanized anti-IgE monoclonal antibody that binds free IgE and reduces FcεRI expression on mast cells and basophils, which decreases IgE-mediated airway inflammation. Its efficacy in severe allergic asthma has been well documented, and mechanistically this same pathway may be relevant to bronchitis when the underlying inflammation is allergic or eosinophilic in nature.

Bronchitis and asthma frequently overlap clinically — eosinophilic bronchitis and asthma share airway inflammatory features, and smoking-induced chronic bronchitis is often discussed alongside asthma-COPD overlap. This overlap is the basis for the TxGNN prediction.

However, it is important to note that the two clinical trials retrieved for this indication (NCT02477332 and NCT02049294) were not designed with bronchitis as the primary diagnosis — the enrolled populations were asthma patients (one for chronic spontaneous urticaria dose-finding, one for asthma with eosinophilic bronchitis as a steroid-sparing sub-study of only 11 patients). The mechanistic link is therefore indirect, inferred through the asthma–bronchitis overlap rather than direct clinical evidence in a bronchitis-diagnosed population.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02477332	Phase 2b	Completed	382	Dose-finding study of QGE031 (ligelizumab, an anti-IgE agent) as add-on therapy in chronic spontaneous urticaria — not a bronchitis-specific trial; included for mechanistic relevance only
NCT02049294	Phase 2/3	Completed	11	Randomized, placebo-controlled trial evaluating whether omalizumab allows steroid dose reduction in patients with asthma and persistent eosinophilic bronchitis; very small sample size limits conclusiveness

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35369622	2022	Cohort	Postepy Dermatologii i Alergologii	Biologic therapy (including omalizumab) may benefit older patients with severe allergic asthma-COPD overlap phenotype
16222080	2005	Review	Clin Rev Allergy Immunol	Overview of omalizumab approval and post-approval experience in moderate-to-severe persistent asthma
30196731	2018	Review	Expert Opin Pharmacother	Discusses treatment challenges in smoking-induced airway disease, including chronic bronchitis, in asthma and asthma-COPD overlap patients
21163396	2010	Review	Rev Mal Respir	French expert review on definitions and treatment of adult asthma exacerbations
26466493	2015	Review	Masui	Japanese perioperative management review noting omalizumab's role in severe allergic asthma alongside bronchitis-related airway inflammation
21121874	2011	Pooled Analysis	Curr Med Res Opin	Pooled safety analysis of omalizumab in children with allergic (IgE-mediated) asthma
17663923	2007	Review	Allergol Immunopathol	General review of monoclonal antibody use in pediatric allergic and respiratory disease
31478531	2019	Case Report	J Investig Allergol Clin Immunol	Rare case of plastic bronchitis following bronchial thermoplasty; not related to omalizumab treatment

Norway Market Information

Omalizumab currently has no market authorization records in Norway (0 licenses, market status: Not Marketed). No product, dosage form, or approved indication text is available for this jurisdiction.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The clinical trial and literature evidence for bronchitis is indirect — the two supporting trials primarily enrolled asthma patients rather than subjects with a confirmed bronchitis diagnosis, and no direct RCT targets bronchitis as the primary endpoint. Combined with the drug's current lack of market authorization in Norway and outstanding blocking safety data gaps, the evidence does not yet support advancing this indication.

To proceed, the following is needed:

TFDA/Norway product labeling with warnings and contraindications (currently a Blocking data gap)
Detailed mechanism of action (MOA) documentation from DrugBank (currently a High-severity data gap)
Dedicated clinical trials enrolling patients with a confirmed (eosinophilic) bronchitis diagnosis, rather than asthma-overlap populations
Clarification of the regulatory pathway, given zero existing Norway market authorizations

Note: Within this same evidence pack, the predicted indication "obstructive lung disease" (rank 3) has substantially stronger, more direct evidence (Evidence Level L1, multiple completed Phase 3 RCTs directly evaluating omalizumab in allergic asthma) and may warrant a separate, higher-priority evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.